<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03811873</url>
  </required_header>
  <id_info>
    <org_study_id>18-004899</org_study_id>
    <nct_id>NCT03811873</nct_id>
  </id_info>
  <brief_title>Assessment of Vertebral Fracture Risk for First Time Liver Transplant Candidates</brief_title>
  <acronym>VFA</acronym>
  <official_title>Assessment of Vertebral Fracture Risk Using VFA and Vertebral Strength Assessment With DXA-Finite Element Analysis in Liver Transplant Recipients in Pretransplant Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigators hypothesize that VFA+ DXA is as effective in evaluation of asymptotic
      vertebral fractures compared to the current gold standard of spine x-ray. In addition, bone
      turnover markers in transplant patients are unknown. The investigators want to investigate
      bone turnover markers (Beta CTX and P1NP) as markers of bone health in patients listed for
      liver transplant.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Testing a single group of participants who are first time liver transplant candidates.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incident of clinical fractures validated by spine x-ray or other imaging (vertebral fracture assessment -VFA)</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of participants experiencing a clinical fracture validated by x-ray or other imaging (VFA) as compared to standard of care ( Spine X-ray)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in bone mineral density by dual x-ray absorptiometry</measure>
    <time_frame>24 months</time_frame>
    <description>Bone mineral density changes seen in end stage liver disease in (grams/cm2) at baseline and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent changes from baseline to 12 months estimation of bone strength derived from finite element analysis</measure>
    <time_frame>24 months</time_frame>
    <description>Bone strength measurements derived from finite element assessment changes from baseline to 12 months and correlation with clinical and radiographic risk of fracture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in bone turnover markers in end stage liver disease</measure>
    <time_frame>24 months</time_frame>
    <description>Bone turnover markers (Beta CTX, P1NP) percent changes from baseline to 12 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Metabolic Bone Disease</condition>
  <condition>Transplant-Related Disorder</condition>
  <condition>Secondary Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single-Arm trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Thoracic spine X-Ray</intervention_name>
    <description>All participants will receive above interventions, in addition to their standard of care. Additionally, 15 patients will undergo CT scan of the lumbar spine at baseline and 1 year follow.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Lumbar Spine X-Ray</other_name>
    <other_name>Bone Mineral Density</other_name>
    <other_name>Vertebral Fracture Assessment</other_name>
    <other_name>Beta CTx</other_name>
    <other_name>P1NP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  First time liver transplant candidates deemed too early for liver transplant

          -  24 hour urine Creatinine clearance of &gt; 40 mg/dl. However bone turnover markers (beta
             CTx and P1NP) will be measured only in those with creatinine clearance &gt;60mg/dl

        Exclusion criteria

          -  Patients with prior solid organ transplantation

          -  Liver/kidney combination will be excluded

          -  Patients with 24 hr. urine creatinine clearance &lt; 40mL/minute

          -  Patients who have been on osteoporosis medications - Bisphosphonates [Fosamax
             (Alendronate), Actonel (Risedronate), Boniva (Ibandronate), or Reclast (Zoledronic
             acid)] Teriparatide (Forteo), Abaloparatide (Tymlos), Denosumab (Prolia), within the
             past 5 years

          -  Use of other systemic medications that can effect bone remodeling including sex
             hormone replacement therapy (estrogen or testosterone), calcitonin, androgen
             deprivation therapy, aromatase inhibitors, or SERMS in the past 6 months

          -  Underlying disease that significantly impacts bone metabolism such as primary
             hyperparathyroidism, hyperthyroidism, Paget's disease of bone, fibrous dysplasia, or
             malignancies with skeletal metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ejigayehu G Abate, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katrina G Taylor</last_name>
    <phone>9049539708</phone>
    <email>Taylor.Katrina@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Satya Dhandapani, B.Tech, M.H.A</last_name>
    <phone>9049533421</phone>
    <email>dhandapani.satya@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>satya dhandapani, B Tech, MHA</last_name>
      <phone>904-953-3421</phone>
      <email>dhandapani.satya@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Katrina G Taylor</last_name>
      <phone>9049539708</phone>
      <email>Taylor.Katrina@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 4, 2019</study_first_submitted>
  <study_first_submitted_qc>January 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Ejigayehu G. Abate</investigator_full_name>
    <investigator_title>Assistant Professor of medicine</investigator_title>
  </responsible_party>
  <keyword>transplant related disorders</keyword>
  <keyword>liver transplant</keyword>
  <keyword>transplant related bone disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Spinal Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

